Vytrus Biotech Achieves 5 Million Euros in Turnover and 2 Million EBITDA in 2024

Vytrus Biotech, a company specialising in active ingredients derived from plant biotechnology for the cosmetics industry, has published its unaudited financial results preview for the 2024 financial year.

Vytrus achieved global sales growth of +35% in 2024 compared to 2023, led by strong growth in the US and European markets (+34%). In addition, the Latin American area increased its sales by +231%, driven by the growth of its business in Brazil and Mexico. The APAC (Asia-Pacific) area joined the stable upward trend with growth of +13%.

Vytrus Biotech now has sales in 39 countries on 5 continents

Significant growth in 2024 has boosted Vytrus sales above €5.04 million for the first time in its history. Anti-aging, hair, sun and sensitive skin applications were the main drivers of growth in all markets.

This good sales performance, combined with good control of operating costs, has allowed Vytrus Biotech to increase its EBITDA by 55% compared to 2023, reaching €2 million for the first time. Operating costs increased by 17%, well below the increase in sales.

These good figures support the biotechnology company’s forecasts, which in 2024 published its Strategic Plan with which it hopes to multiply its sales by three to reach 12 million euros and its EBITDA by four to reach 5 million euros in 2027.

In 2025, Vytrus Biotech will directly market its products to all customer accounts in Spain and France

In France, Vytrus Biotech already directly managed the most relevant accounts, with the distributor taking care of the rest of the clients, which will now be managed directly by the company.

With this direct marketing strategy, both in Spain and France, Vytrus Biotech expects to accelerate the growth of its turnover over the next few years, contributing to the fulfilment of the sales objectives announced in the strategic plan, as well as offering a more direct and personalised service to customers in these countries. To this end, Vytrus Biotech has expanded its sales team in Spain and France, as well as increasing its customer service and logistics capacity to absorb the expected growth.

The Spanish cosmetics market is one of the top 5 cosmetics markets in Europe, with more than 500 companies and an estimated turnover in dermatology and cosmetics of more than 10 billion euros for the year 2023. For its part, the French cosmetics market is one of the most important in the world, with an estimated turnover of around 12 billion euros. Spain and France are some of the main exporters of perfumes and cosmetics, increasingly betting on innovative and sustainable cosmetics, becoming a market opportunity for Vytrus’ active ingredients.

In 2024, Spain has been the main market for Vytrus Biotech products, being the destination of 27% of its sales. Meanwhile, the direct marketing strategy initiated in 2024 in France has allowed this country to be placed in the top 5 of the territories with the most sales in 2024.

__

(Featured image by Mufid Majnun via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in pmfarma. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us